Our earlier studies concentrated on MST1 within the liver, indicating that increased MST1 levels suppressed fat synthesis, enhanced fat oxidation, and proposed diverse materials targeting MST1 for NAFLD treatment, such as microRNA, exosomes, and nanoparticles[31]. Considering the liver and pancreas' location and function correlation, our initial results identified a link between GPR119 and MST1. We verified the connection by observing high-fat diet-induced pancreatic damage in mice and the concurrent downregulation of GPR119[21]. Consequently, investigating drugs targeting GPR119 and elucidating their mechanisms in enhancing pancreatic β-cell function had become the central theme of our research. Terazosin, an antihypertensive drug identified as a GPR119 ligand via molecular docking, was examined for its effects on β-cell function through in vitro and in vivo experiments, considering its broad activation of GPR119, inhibition of the MST1-Foxo3a pathway, and potential implications for glucose and lipid metabolism. Nevertheless, it was crucial not to disregard the impact of alternative drugs on β-cell function, necessitating further exploration. Terazosin, functioning as an α1-adrenergic receptor blocker, was employed to manage hypertension and relieve urinary symptoms in benign prostatic hyperplasia patients, typically prescribed at a dosage of 10mg/day. In the cultured mouse pancreatic β-cell line MIN6, Terazosin selectively activated GPR119. It facilitated cell cycle progression, suppressed inflammation and apoptosis, minimized lipid deposition, and enhanced mitochondrial damage repair and autophagic flow, ultimately enhancing β-cell function. In NAFPD mice, a 1.5mg/kg Terazosin dose markedly ameliorated obesity, hyperglycemia, and insulin sensitivity. Moreover, Terazosin treatment in the pancreas of NAFPD mice hindered the MST1-Foxo3a pathway-induced downregulation of β-cell functional mRNA and protein expression. In GPR119-deficient NAFPD mice, Terazosin failed to induce the beneficial effects observed in regular NAFPD mice, including improvements in obesity, hyperglycemia, and insulin sensitivity, as well as the increase in insulin content and β-cell functional gene expression in the pancreas. In conclusion, our study demonstrated that Terazosin restored normal mitophagy processes and facilitated the recovery of β-cell function by suppressing the MST1-Foxo3a signaling pathway. This finding was particularly important for the complex investigation of GPR119 agonist research and development, as well as for treating and restoring β-cell function in NAFPD.
Terazosin blocks α1-adrenergic receptors on vascular endothelium, prostate, and bladder smooth muscles. This reduces total peripheral vascular resistance, lowers blood pressure, and relaxes smooth muscles, relieving urethral spasm. Regarding tissue distribution, α1-adrenergic receptors are mainly found in vascular smooth muscle, myocardium, prostate, and the brain, whereas α2-adrenergic receptors are expressed in pancreatic tissue[34]. Therefore, Terazosin does not bind to α1-adrenergic receptors in pancreatic tissue, supporting its specific binding to GPR119 in this study. Currently, our findings validated that Terazosin selectively activated GPR119 on the surface of pancreatic β cells, enhancing intracellular CRE promoter activity, increasing cAMP and ATP levels, and regulating the MST1-Foxo3a signaling pathway, thereby improving β cell function.
In contrast to the previously established positive regulatory role in hepatic lipid metabolism, MST1, a serine/threonine kinase at the core of the HIPPO pathway, has recently been recognized as a pivotal factor in pancreatic β-cell apoptosis and dysfunction. Identifying and developing inhibitors targeting MST1 have emerged as a novel approach to safeguard β-cell function[35]. Drug design methods, relying on structure-activity relationships, identified IHMT-MST1-39 and IHMT-MST1-58, along with the high-throughput screening drug Neratinib. These compounds were reported to markedly enhance β-cell survival, alleviating hyperglycemia, and insulin resistance in diabetic mice[36]. The beneficial effects on β-cell function were also corroborated in this study. However, our emphasis on GPCRs, the primary drug target in drug development, uncovered that among the 3622 drugs screened using molecular docking methods, the top 60, upon re-screening, included the confirmed activity of Terazosin. Of course, this does not suggest that other drugs lack research value; conversely, exploring their mechanisms of action on β-cell function via GPR119 holds significant research merit.
Mitophagy is a crucial mechanism for intracellular mitochondrial quality control, facilitating the clearance of damaged mitochondria and maintaining mitochondrial homeostasis. Deleting or inhibiting the MST1 gene contributes to restoring mitophagy. Mice with cardiomyocyte-specific knockout of the MST1 gene show reversed mitophagy, suppressing the apoptotic pathway activated by mitochondria-promoted apoptotic factors[39]. In pancreatic cancer cells, MST1 overexpression inhibits mitophagy, promoting the activation of mitochondria-dependent apoptotic pathways and reducing cell migration[40]. In this study, we confirmed that Terazosin reverses the increased mitochondrial damage induced by MST1 upregulation and validates its positive role in restoring autophagic flux. Consistent with this study's findings, specific knockout of the MST1 gene in diabetic cardiomyopathy mice promotes the autophagic flux process[39], as evidenced by increased levels of LC3-II in the presence of Bafilomycin A1. Considering that autophagic flux involves the formation, fusion, and degradation of autophagic structures, disruptions in these stages can inhibit autophagic flux. Our research reveals an unexpected result: MST1 overexpression suppresses mitophagy gene expression, yet protein levels show an increasing trend. Perhaps a few reported cases can explain this occurrence. In mouse embryonic fibroblasts and myocytes, MST1 loss results in reduced autophagosome-lysosome colocalization, significant accumulation of autophagic structures, high levels of LC3-II and P62, and impaired autophagic flux[41]. Similar to the varied regulatory roles of MST1 in the liver and pancreas, we suspect that pancreatic MST1 may have a regulatory role contrary to previous reports. However, further research is required to confirm this. Furthermore, unlike its regulation of other cellular activities, MST1 overexpression is not affected in its activation of cell apoptosis by Foxo3a silence. It has been reported that MST1 is a direct target and activator of caspase. While initiating the cascade reaction of cell apoptosis, its activity is enhanced by caspase, promoting the apoptotic response circuit[42]. The bidirectional interaction between MST1 and caspase mechanisms determines that their regulation of cell apoptosis relies not only on the status of downstream targets but also on mutual influence.
The forkhead box protein O3a (Foxo3a) is a research hotspot in tumor and drug resistance fields. Although there are few reports on its involvement in metabolic diseases, it unveils a crucial potential role. During streptozotocin (STZ)-induced diabetes stress in pancreatic β-cells, Foxo3a inhibits Parkin-mediated mitochondrial recruitment and mitophagy, thereby impacting the growth of pancreatic β-cells and insulin secretion[44]. In peritoneal macrophages of diabetic mice, Foxo3a, through acetylation, reduces PINK1-dependent mitophagy and inflammasome activation[45]. Additionally, the association between MST1 and Foxo3a has been investigated and confirmed. The reduction in MST1 activity inhibiting Foxo3a activation might be linked to abnormal neural activity patterns and memory impairment[46]. Another study reported that MST1 activation results in phosphorylation and nuclear accumulation of Foxo3a, thereby inhibiting tumor cell migration[47]. In this study, we elucidated the direct regulation of Foxo3a by MST1, enhancing our comprehension of its involvement in diseases related to β-cell dysfunction. Terazosin inhibiting the MST1-Foxo3a signaling pathway through GPR119 is a crucial novel mechanism that elucidates the suppression of mitophagy and compromised β-cell function in NAFPD conditions.
Given the growing correlation between NAFPD and MetS, a disease resulting from the unhealthy lifestyles and dietary habits of contemporary individuals, there is a proposal to incorporate NAFPD as a pancreatic manifestation of MetS in its definition [48]. NAFPD is on the rise as obesity stages and prevalence increase[50]. Elevated pancreatic fat content contributes to impaired glucose tolerance and insulin resistance in the "prediabetes" stage[52]. Given the direct association of NAFPD with excessive fat intake, an experimental NAFPD model in mice can be induced using a high-fat diet. This leads to "prediabetes" symptoms arising from excessive pancreatic fat accumulation within 12 to 18 weeks, aligning with the results presented in this study [53]. Notably, reports suggest "prediabetes" may be a risk factor for NAFPD, indicating a potential vicious cycle[55]. Conversely, the correlation between hypertension and NAFPD is relatively weak[56]. Concerning pancreatic fat accumulation, it's crucial to note: firstly, given the physiological presence of a small amount of fat, describing excessive accumulation as "in situ" fat is more appropriate for NAFPD than the "ectopic" fat seen in NAFLD; secondly, pancreatic fat tends to accumulate primarily in the pancreatic interstitium[7], as opposed to concentrating in the islet cells and acini, distinguishing it from NAFLD. Regarding the pathogenic mechanism, our results confirmed that NAFPD lipotoxicity promoted cell inflammation and apoptosis, inhibited the cell cycle, damaged mitochondria, and impaired the autophagic process, weakening β-cell function across various cellular activities. Presently, most reports support the speculation that fat-induced inflammatory states lead to impaired β-cell function. In PA-induced MIN6 cells, the expression of cytokines interleukin-1 and interleukin-6 is upregulated[57]. In HFD mice, the proportion of perivascular mononuclear inflammatory cell aggregates around the islets significantly increases, and the area of Ly6C-positive activated macrophage markers within the islets also markedly increases[53]. Reports also indicate signs of dedifferentiation and loss of function in pancreatic islet β-cells in HFD mice[58]. Excessive saturated fatty acids may induce differentiation of pancreatic ductal cells into fat cells, leading to increased fat accumulation[59]. Currently, foundational reports on the pathogenic mechanism of NAFPD are lacking. This study provided evidence for exploring the mechanism from multiple perspectives. As confirmed in animal models, diet plays a significant role in the pathogenesis of NAFPD. Therefore, the treatment of NAFPD should prioritize influencing factors such as diet control and weight loss[12], especially in the absence of large randomized clinical trials evaluating NAFPD medications. In small-scale animal and clinical trials, the GLP-1 analog liraglutide has been proven to alleviate the severity of NAFPD[60]. Unfortunately, exenatide's effect on reducing ectopic fat storage is limited to the epicardium and liver and is ineffective for NAFPD[61]. In this study, Terazosin demonstrated beneficial effects on hyperglycemia, obesity, and NAFPD by activating GPR119 rather than acting as a GLP-1R or analog. Considering that both NAFPD and hypertension are considered symptoms within the MetS category, our experimental results strongly suggested that Terazosin should be prioritized as a therapeutic drug for NAFPD patients with concurrent hypertension or those in the "pre-diabetic" stage.
Our study unveiled a novel mechanism governing aberrant β-cell function in NAFPD conditions. The MST1-Foxo3a signaling pathway emerged as a central player, driving mitochondrial damage, and suppressing autophagic flux. Significantly, this represents the inaugural successful drug repurposing strategy to screen GPR119 agonists, exemplified by Terazosin, and assess their influence on β-cell function in NAFPD. Furthermore, the enhancement of mitophagy through Terazosin-induced activation of GPR119 is documented for the first time. Nevertheless, several issues remain unresolved. Additional experiments are required to elucidate the regulatory mechanisms of GPR119 activation on MST1 and its phosphorylation, encompassing the involvement and regulation of cAMP and PKA in this process. Moreover, a more comprehensive understanding of the adverse effects of mitochondrial damage and autophagy inhibition on β-cell function, along with their roles in the pathogenesis of NAFPD, is still required. Hence, forthcoming research should concentrate on enhancing the integrity of the GPR119-MST1-Foxo3a signaling pathway and refining the analysis of autophagic flux alterations at different stages in NAFPD conditions, including their potential mechanisms. Furthermore, Terazosin exhibits common side effects like weakness, palpitations, nausea, peripheral edema, dizziness, and drowsiness. Despite confirming the absence of adverse effects on renal function, its inherent side effects should be taken into account in researching its potential clinical applications for treating NAFPD and hypertension patients. This aspect is also a crucial future avenue for our study.